financetom
Business
financetom
/
Business
/
Neogen's Fiscal Q4 Adjusted Earnings, Revenue Fall; Provides Fiscal 2025 Revenue Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Neogen's Fiscal Q4 Adjusted Earnings, Revenue Fall; Provides Fiscal 2025 Revenue Outlook
Jul 30, 2024 6:22 AM

09:05 AM EDT, 07/30/2024 (MT Newswires) -- Neogen (NEOG) reported fiscal Q4 adjusted earnings Tuesday of $0.10 per share, down from $0.14 a year earlier.

A single analyst polled by Capital IQ expected $0.11.

Revenue for the quarter ended May 31 was $236.8 million, down from $241.8 million a year earlier.

Two analysts surveyed by Capital IQ expected $224.8 million.

For fiscal 2025, the company expects revenue to be between $925 million and $955 million. Two analysts polled by Capital IQ expect $937.6 million.

Price: 18.10, Change: +0.80, Percent Change: +4.62

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Chevron Slows Production at LNG Project in Australia Just Days After Reopening
Chevron Slows Production at LNG Project in Australia Just Days After Reopening
Jun 3, 2024
05:41 PM EDT, 06/03/2024 (MT Newswires) -- Chevron ( CVX ) idled production on a unit of its Gorgon liquified natural gas plant in western Australia, only days after reopening it last week following an extended shutdown for repairs, Bloomberg reported Monday, citing people familiar with the situation. The report did not specify the reason for shut down at the...
Scholar Rock Reports 'Encouraging' Phase 1 Trial Results in Advanced Solid Tumors
Scholar Rock Reports 'Encouraging' Phase 1 Trial Results in Advanced Solid Tumors
Jun 3, 2024
05:44 PM EDT, 06/03/2024 (MT Newswires) -- Scholar Rock ( SRRK ) late Monday reported encouraging data from a phase 1 proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors. The company said the results showed encouraging responses in heavily pretreated and anti-PD-(L)1 resistant patients across multiple tumor types. Analysis of baseline biomarker data in...
Royalty Pharma Prices $1.5 Billion Debt Offering
Royalty Pharma Prices $1.5 Billion Debt Offering
Jun 3, 2024
05:39 PM EDT, 06/03/2024 (MT Newswires) -- Royalty Pharma ( RPRX ) said Monday it priced an offering of $1.5 billion of senior unsecured notes, which is expected to close on June 10. The company is offering $500 million of 5.150% notes due 2029, $500 million of 5.400% notes due 2034, and $500 million of 5.900% notes due 2054. Net...
Boston Scientific Insider Sold Shares Worth $526,029, According to a Recent SEC Filing
Boston Scientific Insider Sold Shares Worth $526,029, According to a Recent SEC Filing
Jun 3, 2024
05:43 PM EDT, 06/03/2024 (MT Newswires) -- Wendy Carruthers, Executive Vice President, Human Resources, on June 03, 2024, sold 6,983 shares in Boston Scientific ( BSX ) for $526,029. Following the Form 4 filing with the SEC, Carruthers has control over a total of 45,628 shares of the company, with 45,628 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/885725/000122520824006513/xslF345X03/doc4.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved